The radioactive pharmacy company may experience a favorable market environment by its accumulated technology and research.
Recently, Beijing Sinotau Pharmaceutical Technology has raised CNY 320 million in Series D, which is led by China Kim Kaide (Xiamen) Innovative Biomedical Equity Investment Fund and followed by Everest VC, Shandong Longmen Venture Investment, and Deye Capital. The raised funds will continue to be used for preclinical development and clinical research of therapeutic and diagnostic radiopharmaceuticals.
Founded in 2005, Sinotau has been focusing on the research and clinical academic promotion of radiopharmaceuticals. The company has developed a number of targeted therapeutic radiopharmaceuticals. At present, the company has four diagnostic drugs and two therapeutic drugs in the clinical trial stage. In July 2020, it completes series C financing and raises CNY 280 million. In the past six months, the company has raised over CNY 600 million.
In 2020, the market size of the global radiopharmaceutical industry reaches USD 0.57 billion, and it is expected to reach USD 1 billion by 2026. The research and clinical application of new radioisotopes such as 177Lu have become the main drivers of the market. However, China's radiopharmaceutical market only accounts for less than 7% of the global market, which has great development potential. As a leading radioactive pharmacy innovator of China, Sinotau has accumulated a bunch of technology and products in the field and formed its moat, which makes it become a company to watch in 2021.